hVIVO CEO reports on “very strong” H1 2023

–News Direct–

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after the specialist contract research organisation released a trading update for first half of 2023 – a period he describes as a "very strong six months." Khan gives his highlights from the update, highlighting a 52% year-on-year increase in revenues to 27.3mln.

He attributes the growth to improved operational efficiencies and the increasing frequency of large concurrent trials. The company reports cash reserves of 31.3 million, even after paying out a special dividend of 3 million, with an order book of 78 million. Addressing a technical detail, Khan mentioned that the company would now report revenue exclusive of other income to align with industry practice. Despite delays at the Medicines and Healthcare Products Regulatory Agency impacting some UK clinical trials, Khan says that hVIVO has successfully managed the situation through its risk mitigation strategy.

For the next six months, hVIVO plans to maintain its growth momentum, with full-year guidance of 53 million in revenue and an ever-expanding order book.

Contact Details

Proactive UK Ltd

+44 20 7989 0813


View source version on newsdirect.com: https://newsdirect.com/news/hvivo-ceo-reports-on-very-strong-h1-2023-441958866


comtex tracking


About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.